Olverembatinib Added to NCCN Guidelines for CML

Olverembatinib has been added to the NCCN's latest guidelines for the treatment of patients with chronic myeloid leukemia.

Related Keywords

China ,Chinese ,Ascentage Pharma ,Dajun Yang ,National Comprehensive Cancer Network ,Practice Guidelines ,Bcr Abl1 Tki ,Olverembatinib ,Chronic Myeloid Leukemia ,Ncml ,